These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11984212)

  • 41. The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia.
    West MS; Herd JA; Ballantyne CM; Pownall HJ; Simpson S; Gould L; Gotto AM
    Control Clin Trials; 1996 Dec; 17(6):550-83. PubMed ID: 8974213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).
    Maitland-van der Zee AH; Jukema JW; Zwinderman AH; Hallman DM; De Boer A; Kastelein JJ; De Knijff P
    Acta Cardiol; 2006 Jun; 61(3):327-31. PubMed ID: 16869455
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of pravastatin (10 mg/day) on progression of coronary atherosclerosis in patients with serum total cholesterol levels from 160 to 220 mg/dl and angiographically documented coronary artery disease. Coronary Artery Regression Study (CARS) Group.
    Tamura A; Mikuriya Y; Nasu M
    Am J Cardiol; 1997 Apr; 79(7):893-6. PubMed ID: 9104901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events.
    Herd JA
    Am J Med; 1998 Jun; 104(6A):42S-49S. PubMed ID: 9684851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.
    Voros S; Joshi PH; Vazquez G; Roth G; Murrieta L; Rinehart S; Qian Z; Miller J
    J Cardiovasc Comput Tomogr; 2010; 4(3):164-72. PubMed ID: 20413364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
    Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
    Pitt B; Ellis SG; Mancini GB; Rosman HS; McGovern ME
    Am J Cardiol; 1993 Jul; 72(1):31-5. PubMed ID: 8517425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation.
    Portal VL; Moriguchi EH; Vieira J; Schio S; Mastalir ET; Buffé F; Bortolini EB; Brüch RS; Rodrigues R
    Arq Bras Cardiol; 2003 Feb; 80(2):156-61, 150-5. PubMed ID: 12640509
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
    Kawada-Watanabe E; Ogawa H; Koyanagi R; Arashi H; Yamaguchi J; Matsui K; Hagiwara N
    J Cardiol; 2017 Mar; 69(3):536-541. PubMed ID: 27349705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Statin treatment for coronary artery plaque composition based on intravascular ultrasound radiofrequency data analysis.
    Nozue T; Yamamoto S; Tohyama S; Umezawa S; Kunishima T; Sato A; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Sozu T; Terashima M; Michishita I
    Am Heart J; 2012 Feb; 163(2):191-9.e1. PubMed ID: 22305836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of baseline lipoprotein and C-reactive protein levels on coronary atheroma regression following high-intensity statin therapy.
    Puri R; Nissen SE; Shao M; Uno K; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Am J Cardiol; 2014 Nov; 114(10):1465-72. PubMed ID: 25282317
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of cholesterol reduction by simvastatin on progression of coronary atherosclerosis: Design, baseline characteristics, and progress of the Multicenter Anti-Atheroma Study (MAAS).
    Dumont JM
    Control Clin Trials; 1993 Jun; 14(3):209-28. PubMed ID: 8339551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Ono T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Cardiol; 2015 Oct; 66(4):353-8. PubMed ID: 25577723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
    de Groot E; Jukema JW; Montauban van Swijndregt AD; Zwinderman AH; Ackerstaff RG; van der Steen AF; Bom N; Lie KI; Bruschke AV
    J Am Coll Cardiol; 1998 Jun; 31(7):1561-7. PubMed ID: 9626835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of mild endurance exercise training and pravastatin on peripheral vasodilatation of forearm resistance vessels in patients with coronary artery disease.
    Allemann Y; Vetter C; Kartal N; Eyer S; Stengel SM; Saner H; Hess OM
    Eur J Cardiovasc Prev Rehabil; 2005 Aug; 12(4):332-40. PubMed ID: 16079640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events.
    Puri R; Nissen SE; Shao M; Elshazly MB; Kataoka Y; Kapadia SR; Tuzcu EM; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2016 Nov; 36(11):2220-2228. PubMed ID: 27515380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
    Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
    Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.